Literature DB >> 26643803

Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells.

Johnathan E Lawrence1, Christopher J Steele2, Richard A Rovin3, Robert J Belton1, Robert J Winn4.   

Abstract

Extent of resection of glioblastoma (GBM) correlates with overall survival. Fluorescence-guided resection (FGR) using 5-aminolevulinic acid (5-ALA) can improve the extent of resection. Unfortunately not all patients given 5-ALA accumulate sufficient quantities of protoporphyrin IX (PpIX) for successful FGR. In this study, we investigated the effects of dexamethasone, desipramine, phenytoin, valproic acid, and levetiracetam on the production and accumulation of PpIX in U87MG cells. All of these drugs, except levetiracetam, reduce the total amount of PpIX produced by GBM cells (p < 0.05). When dexamethasone is mixed with another drug (desipramine, phenytoin, valproic acid or levetiracetam) the amount of PpIX produced is further decreased (p < 0.01). However, when cells are analyzed for PpIX cellular retention, dexamethasone accumulated significantly more PpIX than the vehicle control (p < 0.05). Cellular retention of PpIX was not different from controls in cells treated with dexamethasone plus desipramine, valproic acid or levetiracetam, but was significantly less for dexamethasone plus phenytoin (p < 0.01). These data suggest that medications given before and during surgery may interfere with PpIX accumulation in malignant cells. At this time, levetiracetam appears to be the best medication in its class (anticonvulsants) for patients undergoing 5-ALA-mediated FGR.

Entities:  

Keywords:  5-Aminolevulinic acid; Fluorescence-guided surgery; Glioma; Photodynamic therapy; Protoporphryn IX

Mesh:

Substances:

Year:  2015        PMID: 26643803     DOI: 10.1007/s11060-015-2012-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence.

Authors:  W Stummer; S Stocker; S Wagner; H Stepp; C Fritsch; C Goetz; A E Goetz; R Kiefmann; H J Reulen
Journal:  Neurosurgery       Date:  1998-03       Impact factor: 4.654

2.  Response to: "Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery".

Authors:  P Schucht; J Beck; A Raabe
Journal:  Eur J Surg Oncol       Date:  2015-01-16       Impact factor: 4.424

3.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

Review 4.  5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges.

Authors:  Q Peng; T Warloe; K Berg; J Moan; M Kongshaug; K E Giercksky; J M Nesland
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

5.  Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report.

Authors:  Walter Stummer; Tobias Beck; Wolfgang Beyer; Jan Hendrik Mehrkens; Andreas Obermeier; Nima Etminan; Herbert Stepp; Jörg-Christian Tonn; Reinhold Baumgartner; Jochen Herms; Friedrich Wilhelm Kreth
Journal:  J Neurooncol       Date:  2007-11-23       Impact factor: 4.130

6.  ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma.

Authors:  Yao Jin; Zhang Quan Bin; Huang Qiang; Chu Liang; Chen Hua; Dong Jun; Wang Ai Dong; Lan Qing
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-02       Impact factor: 4.553

7.  5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature.

Authors:  Alessandro Della Puppa; Serena De Pellegrin; Elena d'Avella; Giorgio Gioffrè; Marta Rossetto; Alessandra Gerardi; Giuseppe Lombardi; Renzo Manara; Marina Munari; Marina Saladini; Renato Scienza
Journal:  Acta Neurochir (Wien)       Date:  2013-03-07       Impact factor: 2.216

8.  Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy.

Authors:  L Teng; M Nakada; S-G Zhao; Y Endo; N Furuyama; E Nambu; I V Pyko; Y Hayashi; J-I Hamada
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

9.  5-Aminolevulinic acid-induced protoporphyrin IX fluorescence as immediate intraoperative indicator to improve the safety of malignant or high-grade brain tumor diagnosis in frameless stereotactic biopsies.

Authors:  Gord von Campe; Michael Moschopulos; Martin Hefti
Journal:  Acta Neurochir (Wien)       Date:  2012-04       Impact factor: 2.216

10.  Quantification of Protoporphyrin IX Accumulation in Glioblastoma Cells: A New Technique.

Authors:  Johnathan E Lawrence; Ashish S Patel; Richard A Rovin; Robert J Belton; Catherine E Bammert; Christopher J Steele; Robert J Winn
Journal:  ISRN Surg       Date:  2014-03-04
View more
  9 in total

1.  Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma.

Authors:  Johannes Wach; Ági Güresir; Motaz Hamed; Hartmut Vatter; Ulrich Herrlinger; Erdem Güresir
Journal:  Cancers (Basel)       Date:  2022-04-25       Impact factor: 6.575

2.  F8-SIP mediated targeted photodynamic therapy leads to microvascular dysfunction and reduced glioma growth.

Authors:  G Acker; A Palumbo; D Neri; P Vajkoczy; M Czabanka
Journal:  J Neurooncol       Date:  2016-05-17       Impact factor: 4.130

3.  Recent advances of sonodynamic therapy in cancer treatment.

Authors:  Guo-Yun Wan; Yang Liu; Bo-Wei Chen; Yuan-Yuan Liu; Yin-Song Wang; Ning Zhang
Journal:  Cancer Biol Med       Date:  2016-09       Impact factor: 4.248

4.  The Role of 5-ALA in Low-Grade Gliomas and the Influence of Antiepileptic Drugs on Intraoperative Fluorescence.

Authors:  Sergey A Goryaynov; Georg Widhalm; Maria F Goldberg; Danil Chelushkin; Aldo Spallone; Kosta A Chernyshov; Marina Ryzhova; Galina Pavlova; Alexander Revischin; Ludmila Shishkina; Vadim Jukov; Tatyana Savelieva; Loschenov Victor; Alexander Potapov
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

Review 5.  Photodynamic Therapy for the Treatment of Glioblastoma.

Authors:  Samuel W Cramer; Clark C Chen
Journal:  Front Surg       Date:  2020-01-21

Review 6.  Drug Repositioning in Glioblastoma: A Pathway Perspective.

Authors:  Sze Kiat Tan; Anna Jermakowicz; Adnan K Mookhtiar; Charles B Nemeroff; Stephan C Schürer; Nagi G Ayad
Journal:  Front Pharmacol       Date:  2018-03-16       Impact factor: 5.810

7.  5-aminolevulinic acid-guided surgery for focal pediatric brainstem gliomas: A preliminary study.

Authors:  Jason Labuschagne
Journal:  Surg Neurol Int       Date:  2020-10-08

Review 8.  Analysis of Factors Affecting 5-ALA Fluorescence Intensity in Visualizing Glial Tumor Cells-Literature Review.

Authors:  Marek Mazurek; Dariusz Szczepanek; Anna Orzyłowska; Radosław Rola
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

9.  Correlation of Intraoperative 5-ALA-Induced Fluorescence Intensity and Preoperative 11C-Methionine PET Uptake in Glioma Surgery.

Authors:  Kazuhide Shimizu; Kaoru Tamura; Shoko Hara; Motoki Inaji; Yoji Tanaka; Daisuke Kobayashi; Takashi Sugawara; Hiroaki Wakimoto; Tadashi Nariai; Kenji Ishii; Ichiro Sakuma; Taketoshi Maehara
Journal:  Cancers (Basel)       Date:  2022-03-11       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.